Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteers

Trial Profile

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteers

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 May 2017

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Allergic conjunctivitis; Atopic dermatitis; Coronary artery restenosis; Eye disorders; Graft-versus-host disease; Interstitial lung diseases; Intestinal transplant rejection; Lupus nephritis; Myasthenia gravis; Psoriasis; Rheumatoid arthritis; Transplant rejection; Ulcerative colitis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 08 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 25 Nov 2016 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top